Allos Therapeutics Inc. (ALTH)

Potential 100x return positive points :

• Insider buying 1,034,580 shares between $5.50 to $5.80
• Potential huge return with approval of EFAPROXYN.
• Good Business strategy and well executed -Our goal is to become a profitable biopharmaceutical development and marketing company. The key elements of our business strategy are to:
  * Focus on the oncology market. We intend to continue to focus our drug development efforts on the oncology market. We believe the oncology market is attractive due to its large market size, continual demand for safer and more effective cancer treatments, well-characterized endpoints, and potential for expedited regulatory review.
  *Obtain regulatory approval to market EFAPROXYN. We are currently focused on completing our Phase 3 ENRICH trial and, if the results are positive, obtaining regulatory approval in the United States to market EFAPROXYN as an adjunct to WBRT for the treatment of brain metastases originating from breast cancer. We may pursue regulatory approvals in other countries if deemed strategically and economically feasible. In addition, in the event we obtain regulatory approval to market EFAPROXYN, we intend to expand our clinical development activities involving EFAPROXYN to pursue additional labels for which there is evidence of clinical benefit.
  *Advance the development of PDX and RH1. We plan to evaluate PDX and RH1 for oncology use as single agents or in combination with other therapies in target indications that we believe offer the most expedient pathway to marketing approval. In the near-term, we plan to initiate a Phase 2 trial of PDX in PTCL, which we hope may provide the basis to obtain marketing approval for PDX in this indication. *Expand our product candidate portfolio. We may pursue opportunities from time to time to expand our product candidate portfolio by identifying and evaluating new compounds that have demonstrated potential in preclinical or clinical studies and are synergistic with our existing oncology portfolio. Our intent is to build a strong and continual pipeline of novel and powerful drug candidates. *Develop sales and marketing capabilities to maximize the commercial potential of our product candidates . We currently retain exclusive worldwide commercial rights to EFAPROXYN, PDX and RH1 for all target indications. We intend to develop sales and marketing capabilities, either internally or through a combination of contract relationships or strategic collaborations, to market our products in the United States. We intend to enter into co-promotion or out-licensing arrangements to reach all markets outside the United States.